文献速递儿童青少年精神心境障碍精神分裂症与精神病性障碍

磷酸二酯酶在神经发育障碍病理生理中的作用

Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders.
PubMed 文献 · Mol Psychiatry · 2021-01-07

本文综述磷酸二酯酶(PDEs)在神经发育障碍病理生理中的作用,整合患者遗传变异、动物模型表型及PDE抑制剂药理效应证据,指出PDE调节剂对改善学习记忆损害、抑郁相关行为异常及社交缺陷具有治疗潜力,相关临床试验正在阿尔茨海默病、精神分裂症、抑郁和孤独症谱系障碍中开展。

要点

  • PDEs水解cAMP/cGMP,调节记忆、认知等神经行为功能。
  • PDE2A、PDE3、PDE4/4D、PDE10A抑制剂治疗孤独症谱系障碍和智力障碍是重要进展。
  • PDE调节剂临床试验正在阿尔茨海默病、精神分裂症、抑郁和孤独症谱系障碍中开展。

核心结论

  • PDE调节剂对以学习记忆损害、抑郁相关行为异常和社交缺陷为特征的神经发育疾病具有治疗潜力。

研究设计与样本

  • 综述整合神经发育障碍患者的遗传变异、动物模型表型及PDE抑制剂药理效应证据。

主要发现

  • PDEs家族含11个亚家族,主要催化cAMP、cGMP或两者水解。
  • cAMP和cGMP是调节记忆、认知等神经行为功能的关键第二信使。
  • PDE2A、PDE3、PDE4/4D和PDE10A抑制剂用于治疗孤独症谱系障碍和智力障碍是重要进展。
  • 临床试验正在阿尔茨海默病、精神分裂症、抑郁和孤独症谱系障碍患者中开展。
  • 文中聚焦Down综合征、脆性X综合征、Rett综合征及CC2D1A基因相关智力障碍中cAMP和/或cGMP失调。

临床怎么用

  • PDE调节剂可能为缺乏特异性疗法的孤独症谱系障碍和智力障碍提供治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. They are members of a family of proteins that includes 11 subfamilies with different substrate specificities. Their main function is to catalyze the hydrolysis of cAMP, cGMP, or both. cAMP and cGMP are two key second messengers that modulate a wide array of intracellular processes and neurobehavioral functions, including memory and cognition. Even if these enzymes are present in all tissues, we focused on those PDEs that are expressed in the brain. We took into consideration genetic variants in patients affected by neurodevelopmental disorders, phenotypes of animal models, and pharmacological effects of PDE inhibitors, a class of drugs in rapid evolution and increasing application to brain disorders. Collectively, these data indicate the potential of PDE modulators to treat neurodevelopmental diseases characterized by learning and memory impairment, alteration of behaviors associated with depression, and deficits in social interaction. Indeed, clinical trials are in progress to treat patients with Alzheimer's disease, schizophrenia, depression, and autism spectrum disorders. Among the most recent results, the application of some PDE inhibitors (PDE2A, PDE3, PDE4/4D, and PDE10A) to treat neurodevelopmental diseases, including autism spectrum disorders and intellectual disability, is a significant advance, since no specific therapies are available for these disorders that have a large prevalence. In addition, to highlight the role of several PDEs in normal and pathological neurodevelopment, we focused here on the deregulation of cAMP and/or cGMP in Down Syndrome, Fragile X Syndrome, Rett Syndrome, and intellectual disability associated with the CC2D1A gene.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Delhaye S, Bardoni B. Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. Mol Psychiatry. 2021. PMID: 33414502. doi:10.1038/s41380-020-00997-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。